With lower than usual growth in Pharma and declining LSI, JUBILANT sales Change in Estimates | Target | Reco were 3% lower than our estimates while adj. EBITDA and adj. PAT were ahead by 5% and 6% respectively. This is due to better adj. gross margin by 40bps...